SCHEMBL269559

SCHEMBL269559

CC(C)(C)c1ccc2cc(C(=O)NCc3ccnc4ccccc34)ccc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.49
LMNA P02545 3/20 0.49
RAB9A P51151 1/20 0.49
HTT P42858 2/20 0.48
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
PABPC1 P11940 1/20 0.47
EIF4H Q15056 1/20 0.47
ALDH1A1 P00352 3/20 0.46
MAPT P10636 2/20 0.46
HDAC3 O15379 1/20 0.46
HDAC4 P56524 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC7 Q8WUI4 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC10 Q969S8 1/20 0.46
HDAC11 Q96DB2 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
HDAC9 Q9UKV0 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4787180 0.89 FLT1 (0.48) SMN1; SMN2ALDH1A1MAPTHDAC3HDAC4
SCHEMBL264360 0.86 SMN1; SMN2 (0.48) SMN1; SMN2LMNAHTTMEN1KMT2A
SCHEMBL263436 0.85 MEN1 (0.47) RAB9AMEN1KMT2APABPC1EIF4H
Hydrochloric Acid SCHEMBL264982 0.84 MEN1 (0.47) RAB9AMEN1KMT2APABPC1EIF4H
SCHEMBL263929 0.80 SMN1; SMN2 (0.45) SMN1; SMN2LMNARAB9AMEN1KMT2A
SCHEMBL263858 0.80 SMN1; SMN2 (0.43) SMN1; SMN2LMNAHTTALDH1A1MAPT
SCHEMBL264854 0.80 MMP2 (0.47) SMN1; SMN2LMNARAB9AMEN1KMT2A
SCHEMBL2909920 0.76 NR1H4 (0.54) SMN1; SMN2LMNARAB9AHTTMEN1
SCHEMBL2906747 0.76 EPHX2 (0.51) SMN1; SMN2LMNARAB9AHTTMEN1
SCHEMBL14147908 0.74 SCN9A (0.52) RAB9AMEN1KMT2AADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253740-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS PFIZER INC 2009-10-08 US claimed
US-8134004-B2 Substituted N-bicyclicalkyl bicycliccarboxyamide compounds PFIZER INC. (US) 2012-03-13 US disclosed
US-8134004-B2 Substituted N-bicyclicalkyl bicycliccarboxyamide compounds PFIZER INC. (US) 2012-03-13 US disclosed
US-20090253740-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS PFIZER INC 2009-10-08 US disclosed
US-20090253740-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS PFIZER INC 2009-10-08 US disclosed
WO-2008007211-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLIC CARBOXYAMIDE COMPOUNDS PFIZER JAPAN INC. (JP) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253740-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS OPRL1, CNR1, TRPV1 SMN1; SMN2 1166/4885LMNA 2567/4885RAB9A 1112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.